Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/III trial of adsorbed tetanus vaccine in adults
CTR20253398Phase 3Active
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of Tetanus Vaccine (Adsorbed) in Tetanus (2 arms), sponsored by Walvax Biotechnology Co., Ltd. Primary endpoints: Phase I adverse reaction/event incidence and Phase III seroconversion rate of serum tetanus toxoid antibody. Started Sep 2025; status: active.
02
Drugs
Tetanus Vaccine (Adsorbed)
03
Conditions
Tetanus
Beyond the preview
Go deeper on CTR20253398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253398.